Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01343693 · ClinicalTrials.gov registry record
MaxAn Post Market Surveillance Validation
A clinical trial of Tumor and Fracture, sponsored by Zimmer Biomet.
- Completed
- Registry status
- 119
- Enrollment target
- 6
- Study locations
NCT01343693: Completed study of Tumor and Fracture, sponsored by Zimmer Biomet.
NCT01343693 is a study of Tumor and Fracture that has completed, run by Zimmer Biomet. The registered enrollment target is 119 participants, below the 178-participant average among 18 other Tumor trials with a reported enrollment target (33% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01343693, a study of Tumor and Fracture, has completed, sponsored by Zimmer Biomet.
- COMPLETED
- Registry status
- 119 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study is being performed to document the outcomes of subjects using our MaxAn Anterior Cervical Plate and assess them for Adjacent level Disease. All subjects will be followed for 2 years.
Primary Outcome
Qualitatively assessed by an independent Radiologist using lateral radiographs Grade 0 - None Grade 1 - Mild (if the ossification extended across \<50% of the disc space) Grade 2 - Moderate (if the ossification extended across ≥ 50% of the disc space) Grade 3 - Severe (if there is complete bridging of the adjacent disc space)
Study Locations (6)
Alabama
- Montgomery Spine Center - Montgomery
Florida
- Tallahassee Neurological Clinic - Tallahassee
Indiana
- Community Neurosurgery - Indianapolis
Maryland
- Maryland Spine and Brain - Annapolis
North Carolina
- Cary Orthopedics - Cary
Texas
- DFW Center for Spinal Disorders - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2011-06 |
| Est. Completion | 2018-01 |
What the finished NCT01343693 record still lists
NCT01343693 is an observational study that tracks outcomes without assigning an intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 178-participant average among 18 other Tumor trials with a reported enrollment target (33% lower).
The record links to 4 conditions, with Tumor appearing as the primary indexed condition, and to 0 interventions.
NCT01343693 lists 6 locations in 6 states (Alabama, Florida, Indiana).
Frequently Asked Questions
What is clinical trial NCT01343693 about?
NCT01343693 is a clinical study titled "MaxAn Post Market Surveillance Validation". This study is being performed to document the outcomes of subjects using our MaxAn Anterior Cervical Plate and assess them for Adjacent level Disease. All subjects will be followed for 2 years.
What is the current status of trial NCT01343693?
This trial is currently completed. The enrollment target is 119 participants. The study started on 2011-06. Estimated completion is 2018-01.
What conditions does trial NCT01343693 study?
This clinical trial studies the following conditions: Tumor, Fracture, Deformity, DDD.
Who is sponsoring clinical trial NCT01343693?
This trial is sponsored by Zimmer Biomet, which has 115 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01343693 being conducted?
This trial has 6 study locations across Alabama, Florida, Indiana, Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01343693's enrollment target sits among peer trials
119 7th of 18 higher than 12 of 18 other Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Decoupling Immunotherapy Toxicity and Cancer Response
RECRUITING
-
A Study of Live Tumor Fragments of Surgical Resections
RECRUITING
-
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
RECRUITING · Phase 2
-
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
RECRUITING · Phase 2
-
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
RECRUITING · Phase 2
-
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia